CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

Positive
AI Analysis

Summary

Jazz Pharmaceuticals is acquiring Actio Biosciences, a rare epilepsy drugmaker, in a potentially $1.3 billion deal with $820 million upfront. The acquisition continues a trend of increased private biotech buyouts in 2026.

Importance:7/10
Sentiment:
0.50
acquisitionrare diseaseepilepsyM&A
Related Companies

Read the original article

Published by BioPharma Dive on August 10, 2026 3:36 PM

Read Original